DrugDashboards

Clindamycin Phosphate

Clindamycin Phosphate Gel USP, 1% · CLINDAMYCIN PHOSPHATE 10 mg/g · Gel · Topical · Encube Ethicals, Inc.

NDC 21922-0027-05 · 1 TUBE in 1 CARTON / 30 g in 1 TUBE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price is down 17% over the past year, to $0.1394 per gram. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 21922-0027-07) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.3948per unit
middle half $0.2753$0.7010 · 5,133 plans · Apr 1, 2026
Est. net of rebates
≈ $0.3948
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
93%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 81%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.

NADAC price per unit

$0$0.5$1.00$1.50Apr 2021Sep 2026$0.1394
66 price points · per GMSource: CMS NADAC

Medicaid spend (2025)

$2.1M
119,010 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for clindamycin phosphate (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA212438
TE code
AB1
Approval date
Mar 11, 2021
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Clindamycin Phosphate Gel USP, 1% (Gel)

LabelerStrengthFirst seenLast seen
Encube Ethicals, Inc.CLINDAMYCIN PHOSPHATE 10 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clindamycin Phosphate — NDC 21922-0027-05," retrieved September 3, 2026, https://drugdashboards.com/drug/21922002705.

Free to cite with attribution — see how the data is put together.